Skip to main content

CORRECTION article

Front. Pediatr., 13 January 2022
Sec. Pediatric Cardiology
Volume 9 - 2021 | https://doi.org/10.3389/fped.2021.834454

Corrigendum: Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

This article is a correction to:

  1. Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

    1. Read original article
\nAna García-Robles,,Ana García-Robles1,2,3Ana Gimeno Navarro,Ana Gimeno Navarro1,2María del Mar Serrano MartínMaría del Mar Serrano Martín4María Jos Prraga QuilesMaría José Párraga Quiles5Anna Parra Llorca,Anna Parra Llorca1,2Jos Luis Poveda-AndrsJosé Luis Poveda-Andrés3Mximo Vento Torres,Máximo Vento Torres1,2Marta Aguar Carrascosa, Marta Aguar Carrascosa1,2*
  • 1Neonatal Research Group, Health Research Institute La Fe, University and Polytechnic Hospital La Fe, Valencia, Spain
  • 2Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain
  • 3Division of Pharmacy, University and Polytechnic Hospital La Fe, Valencia, Spain
  • 4Division of Neonatology, Regional University Hospital of Malaga, Málaga, Spain
  • 5Division of Neonatology, University Hospital Reina Sofía, Córdoba, Spain

A Corrigendum on
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

by García-Robles, A., Gimeno Navarro, A., Serrano Martín, M. d. M., Párraga Quiles, M. J., Parra Llorca, A., Poveda-Andrés, J. L., Vento Torres, M., and Aguar Carrascosa, M. (2020). Front. Pediatr. 8:372. doi: 10.3389/fped.2020.00372

In the original article, we neglected to include “Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”” in the Funding Statement.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ductus, paracetamol, efficacy, safety, pharmacokinetics, pharmacogenetics

Citation: García-Robles A, Gimeno Navarro A, Serrano Martín MdM, Párraga Quiles MJ, Parra Llorca A, Poveda-Andrés JL, Vento Torres M and Aguar Carrascosa M (2022) Corrigendum: Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol. Front. Pediatr. 9:834454. doi: 10.3389/fped.2021.834454

Received: 13 December 2021; Accepted: 16 December 2021;
Published: 13 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 García-Robles, Gimeno Navarro, Serrano Martín, Párraga Quiles, Parra Llorca, Poveda-Andrés, Vento Torres and Aguar Carrascosa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Marta Aguar Carrascosa, bWFyYWNhJiN4MDAwNDA7YWx1bW5pLnV2LmVz

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.